Skip to content
value.today

Kalobios Pharmaceuticals Inc.

Formerly Horizon Biotechnologies, Inc.

Total raised
$37 M
3 rounds on record
Latest round
$12 M
Jun 2016
First round on record
May 2012
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Kalobios Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2016$12 MNo. 3$10 to $50 million

Kalobios Pharmaceuticals Inc.: Raise no. 3, Jun 2016

Investors in this round

8 investors had bought by the notice of Jul 15, 2016: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cameron Durrant · Executive Officer, Director
  • Dean Witter III · Executive Officer
  • Morgan Lam · Executive Officer
  • Dale Chappell · Director
  • Ezra Friedberg · Director
  • Ronald Barliant · Director
  • Timothy Morris · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cameron Durrant, Chairman and Chief Executive Officer. Newest notice filed Jul 15, 2016. Read the notice at the SEC.

equity, optionsSEC
Dec 2015$8 MNo. 2$2 to $10 million

Kalobios Pharmaceuticals Inc.: Raise no. 2, Dec 2015

Investors in this round

18 investors had bought by the notice of Jan 6, 2016: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $9 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Moradi · Director
  • Michael Harrison · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Moradi, Non-Executive Chairman. Newest notice filed Jan 6, 2016. Read the notice at the SEC.

equitySEC
May 2012$17 MNo. 1$10 to $50 million

Kalobios Pharmaceuticals Inc.: Raise no. 1, May 2012

Investors in this round

8 investors had bought by the notice of May 21, 2012: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pritchard · Executive Officer, Director
  • Jeanne Jew · Executive Officer
  • Brigitte Smith · Director
  • Denise Gilbert · Director
  • Dennis Henner · Director
  • Gary Lyons · Director
  • James Healy · Director
  • Ray Withy · Director
  • Ted Love · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeanne Jew, Secretary. Newest notice filed May 21, 2012. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kalobios Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2016).

    SEC Form D · Jul 2016

  • The industry group it chose in its notices: Other.

    SEC Form D · Jul 2016

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Kalobios Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kalobios Pharmaceuticals Inc.
NameRoleNamed in
Cameron DurrantExecutive officerJul 2016
Dean Witter IIIExecutive officerJul 2016
Morgan LamExecutive officerJul 2016
David PritchardExecutive officerMay 2012
Jeanne JewExecutive officerMay 2012
Cameron DurrantDirectorJul 2016
Dale ChappellDirectorJul 2016
Ezra FriedbergDirectorJul 2016
Ronald BarliantDirectorJul 2016
Timothy MorrisDirectorJul 2016
David MoradiDirectorJan 2016
Michael HarrisonDirectorJan 2016
Brigitte SmithDirectorMay 2012
David PritchardDirectorMay 2012
Denise GilbertDirectorMay 2012
Dennis HennerDirectorMay 2012
Gary LyonsDirectorMay 2012
James HealyDirectorMay 2012
Ray WithyDirectorMay 2012
Ted LoveDirectorMay 2012